Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Poolbeg upbeat on research into potential drug market
(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday, in preventing cancer immunotherapy-induced cytokine release syndrome (CRS) through oral delivery. The AIM-traded firm said the research suggested potential applications of POLB 001 in rare and orphan blood cancers, aligning with its commitment to addressing severe medical conditions.
In addition to the promising outlook for POLB 001, Poolbeg said it intended to advance its development alongside its existing portfolio, including programmes targeting influenza, AI-driven drug discovery, and oral delivery of GLP-1 for metabolic disorders.
With the field of cancer immunotherapies projected to reach $100bn to $140bn by 2030, the demand for effective CRS management was described as imminent.
CRS-related hospitalisation costs amount to an estimated $5.5bn, which Poolbeg said underscored the urgent need for preventative interventions.
Notably, Poolbeg's recent in vivo results for POLB 001 showed promising outcomes in ameliorating CRS symptoms, accompanied by dose-dependent reductions in proinflammatory cytokines.
The development of an oral preventative therapy held potential not only to alleviate healthcare system burdens, but also to enhance patient access to life-saving treatments, possibly extending beyond specialist centres.
"Rare and orphan disease medicines fit Poolbeg's efficient capital model particularly well," said chief executive officer Jeremy Skillington.
"Clinical development is typically more cost efficient and the market opportunity remains high because of the high unmet medical need.
"There is also a very active merger and acquisition market in this sector which Amryt took advantage of."
Skillington said the company saw the strategic approach as "highly complementary" to its existing programmes.
"The former Amryt team that have joined Poolbeg have an exceptional track record, have hit the ground running and are aligned with our vision of rapidly generating revenues and creating value for shareholders."
At 1412 GMT, shares in Poolbeg Pharma were down 0.74% at 9.28p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.